Souhaitez-vous accéder aux communiqués récents ?

CNS CEO David Harrington joins the Brain to Brain podcast to discuss brain injury recovery, advocacy and why it is never too late to pursue rehabilitation.

Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)

If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma...

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage

Researchers at IOB developed targeted delivery of healthy mitochondria to diseased cells, opening new paths for treating mitochondrial disorders.

Trial attorney Taylor Ernst publishes The Ernst Way, the first complete methodology for litigating traumatic brain injury cases (Ernst Media, 2025).

SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...

T. Rowe Price CEO Robert Sharps joins Longeviti Neuro Solutions board, signaling growth as the company scales its AI-enabled neurotechnology platform.

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -  - Harnessing increased data and cutting-edge supercomputing potentially unlocks new...

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks...